title: Immunohistochemical features of lacrimal gland epithelial tumors.
abstract: OBJECTIVE
  To investigate the immunohistochemical features of ocular adnexal pleomorphic adenoma and adenoid cystic carcinoma.
  
  
  METHODS
  Retrospective clinicopathologic study.
  
  
  METHODS
  Clinical records and microscopic slides of 7 cases of each tumor type were reviewed. Immunohistochemical probes for Ki-67 and p53, and newer nuclear markers MYB for adenoid cystic carcinoma and PLAG1 for pleomorphic adenoma, were employed.
  
  
  RESULTS
  Pleomorphic adenomas were asymptomatic, whereas adenoid cystic carcinomas were painful. No pleomorphic adenomas recurred; 4 adenoid cystic carcinomas recurred, resulting in 3 deaths. Unusual histopathologic variants for which immunohistochemistry proved useful included a myoepithelioma, an atypical pleomorphic adenoma, tubular and solid/basaloid variants of adenoid cystic carcinoma, and a morphologically heterogeneous adenoid cystic carcinoma of a Wolfring gland. For the pleomorphic adenomas, the average Ki-67 proliferation index was 3.8%; p53 was weakly staining, with an average positivity of 18.5%; PLAG1 was strongly positive in all cases; MYB was negative in 5 cases and weakly focally positive in 2 cases. For the adenoid cystic carcinomas, the average Ki-67 proliferation index was 29.1%; p53 stained positively and strongly with an average of 39%; none stained positively for PLAG1; and 6 out of 7 were MYB positive.
  
  
  CONCLUSIONS
  Between pleomorphic adenoma and adenoid cystic carcinoma, there was no overlap in Ki-67 positivity. Positivity for p53 showed overlap in only one lesion of each type. PLAG1 and MYB positivity were highly discriminating between pleomorphic adenoma and adenoid cystic carcinoma. Immunohistochemical analysis should be investigated further for its role in the evaluation of pleomorphic adenoma and adenoid cystic carcinoma.
authors: David G. Cogan Laboratory of Ophthalmic Pathology, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
authors: Pia R
authors: PR
authors: Mendoza
authors: Frederick A
authors: FA
authors: Jakobiec
authors: Jeffrey F
authors: JF
authors: Krane
mesh_terms: D008949:Adenoma, Pleomorphic / Q000378:metabolism / Q000473:pathology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D003528:Carcinoma, Adenoid Cystic / Q000378:metabolism / Q000473:pathology*; D002648:Child; D004268:DNA-Binding Proteins / Q000378:metabolism; D005134:Eye Neoplasms / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000378:metabolism; D007766:Lacrimal Apparatus Diseases / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D020598:Proto-Oncogene Proteins c-myb / Q000378:metabolism; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D019394:Ki-67 Antigen; C104382:PLAG1 protein, human; D020598:Proto-Oncogene Proteins c-myb; D016159:Tumor Suppressor Protein p53